---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021996"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:17:12.847509+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma neffy FDA Panel Vote 'Favorable'; Q1 Net Loss $15.0M, Cash $264.5M

## Summary
- FDA advisory committee voted 16:6 (adults) and 17:5 (children) that neffy benefit-risk is favorable.
- PDUFA target action date anticipated mid-2023; NDA and MAA under review in US and EU.
- Cash $264.5M, sufficient for at least three years including planned neffy launch.
- Net loss $15.0M for Q1 2023; R&D $6.6M, G&A $12.2M.
- Commercial launch prep underway with planned 125-person salesforce.

## SEC filing metadata
- accession: 0000950170-23-021996
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017023021996/0000950170-23-021996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017023021996/spry-20230515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021996
- JSON: https://secwatch.observer/filing/0000950170-23-021996.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021996.txt

## Key facts
- Earnings Releases
  ARS Pharmaceuticals, Inc. reported the quarter ended March 31, 2023 results: net income $15.0 million.
  - Period: the quarter ended March 31, 2023
  - Net income: $15.0 million
  - Result: reported results
  source text: Net loss was $15.0 million for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000095017023021996/0000950170-23-021996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.